Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation.
Trunečka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, Troisi RI, Baccarani U, Ortiz de Urbina J, Wall W; Tacrolimus Prolonged Release Liver Study Group. Trunečka P, et al. Among authors: wall w. Am J Transplant. 2010 Oct;10(10):2313-23. doi: 10.1111/j.1600-6143.2010.03255.x. Epub 2010 Sep 14. Am J Transplant. 2010. PMID: 20840481 Free article. Clinical Trial.
Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain V, Ghent C, Marotta P, Grant D, Wall W, Tchervenkov J, Barkun J, Roy A, Marleau D, McAlister V, Peltekian K. Greig P, et al. Among authors: wall w. Liver Transpl. 2003 Jun;9(6):587-95. doi: 10.1053/jlts.2003.50102. Liver Transpl. 2003. PMID: 12783400 Free article. Clinical Trial.
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS. Yoshida EM, et al. Liver Transpl. 2005 Sep;11(9):1064-72. doi: 10.1002/lt.20490. Liver Transpl. 2005. PMID: 16123958 Free article. Clinical Trial.
The role of anti-non-Gal antibodies in the development of acute humoral xenograft rejection of hDAF transgenic porcine kidneys in baboons receiving anti-Gal antibody neutralization therapy.
Chen G, Sun H, Yang H, Kubelik D, Garcia B, Luo Y, Xiang Y, Qian A, Copeman L, Liu W, Cardella CJ, Wang W, Xiong Y, Wall W, White DJ, Zhong R. Chen G, et al. Among authors: wall w. Transplantation. 2006 Jan 27;81(2):273-83. doi: 10.1097/01.tp.0000188138.53502.de. Transplantation. 2006. PMID: 16436972
An analysis of late deaths after liver transplantation.
Asfar S, Metrakos P, Fryer J, Verran D, Ghent C, Grant D, Bloch M, Burns P, Wall W. Asfar S, et al. Among authors: wall w. Transplantation. 1996 May 15;61(9):1377-81. doi: 10.1097/00007890-199605150-00016. Transplantation. 1996. PMID: 8629300
Improvement in human decay accelerating factor transgenic porcine kidney xenograft rejection with intravenous administration of gas914, a polymeric form of alphaGAL.
Zhong R, Luo Y, Yang H, Garcia B, Ghanekar A, Luke P, Chakrabarti S, Lajoie G, Phillips MJ, Katopodis AG, Duthaler RO, Cattral M, Wall W, Jevnikar A, Bailey M, Levy GA, Grant DR. Zhong R, et al. Among authors: wall w. Transplantation. 2003 Jan 15;75(1):10-9. doi: 10.1097/00007890-200301150-00003. Transplantation. 2003. PMID: 12544864
337 results